These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24684774)

  • 1. Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial.
    Lamy A; Tong W; Jung H; Gafni A; Singh K; Tyrwhitt J; Yusuf S; Gerstein HC;
    J Diabetes Complications; 2014; 28(4):553-8. PubMed ID: 24684774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial.
    Cukierman-Yaffe T; Bosch J; Diaz R; Dyal L; Hancu N; Hildebrandt P; Lanas F; Lewis BS; Marre M; Yale JF; Yusuf S; Gerstein HC;
    Lancet Diabetes Endocrinol; 2014 Jul; 2(7):562-72. PubMed ID: 24898834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial.
    Simpson SH; Lier DA; Majumdar SR; Tsuyuki RT; Lewanczuk RZ; Spooner R; Johnson JA
    Diabet Med; 2015 Jul; 32(7):899-906. PubMed ID: 25594919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use.
    Lombard L; Distiller L; Aalbers J
    Cardiovasc J Afr; 2012 Jul; 23(6):357-8. PubMed ID: 23091824
    [No Abstract]   [Full Text] [Related]  

  • 6. Basal insulin and cardiovascular and other outcomes in dysglycemia.
    ; Gerstein HC; Bosch J; Dagenais GR; Díaz R; Jung H; Maggioni AP; Pogue J; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S
    N Engl J Med; 2012 Jul; 367(4):319-28. PubMed ID: 22686416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design.
    Sun X; Guo L; Shang H; Ren M; Wang Y; Huo D; Lei X; Wang H; Zhai J
    Trials; 2015 Nov; 16():496. PubMed ID: 26530718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes.
    Roman G; Hancu N
    Horm Metab Res; 2009 Feb; 41(2):116-22. PubMed ID: 19214921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin therapy for diabetes mellitus: treatment regimens and associated costs.
    Charbonnel B; Penfornis A; Varroud-Vial M; Kusnik-Joinville O; Detournay B
    Diabetes Metab; 2012 Apr; 38(2):156-63. PubMed ID: 22172400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study.
    Yang L; Christensen T; Sun F; Chang J
    Value Health; 2012; 15(1 Suppl):S56-9. PubMed ID: 22265068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
    Holden SE; Jenkins-Jones S; Morgan CL; Schernthaner G; Currie CJ
    Diabetes Obes Metab; 2015 Apr; 17(4):350-62. PubMed ID: 25399739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current cost analysis in the management of diabetes mellitus].
    Oberender P
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S110-4; discussion S124-6. PubMed ID: 18686219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
    Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
    J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden.
    Quilici S; Chancellor J; Maclaine G; McGuire A; Andersson D; Chiasson JL
    Int J Clin Pract; 2005 Oct; 59(10):1143-52. PubMed ID: 16178980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.